Boutique Biotech

Boutique Biotech

Share this post

Boutique Biotech
Boutique Biotech
Astria Therapeutics in the spotlight (part IV)

Astria Therapeutics in the spotlight (part IV)

Locking in >150% profits, upcoming phase 1 expectations, how we're trading, and why...

Bohdan (Bo) Khomtchouk, Ph.D.'s avatar
Bohdan (Bo) Khomtchouk, Ph.D.
Dec 02, 2022
∙ Paid

Share this post

Boutique Biotech
Boutique Biotech
Astria Therapeutics in the spotlight (part IV)
Share

Since reporting on Astria Therapeutics (ATXS) back in September, the Company expects preliminary results from their Phase 1a trial of STAR-0215 by year-end 2022. The trial aims to establish the prolonged half-life and demonstrate inhibition of plasma kallikrein activity which, if favorable, would provide proof-of-mechanism for STAR-0215 as a potential b…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Bohdan (Bo) Khomtchouk, Ph.D.
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share